Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 13/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | WDR5 | P61964 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7868247 | 0.91 | NPC1 (0.47) | PKMMAPK1ABCB1PIK3CAPDE4B | |
| SCHEMBL7865291 | 0.91 | PKM (0.45) | PKMMAPK1ABCB1PIK3CAPDE4B | |
| SCHEMBL7868232 | 0.90 | PIK3CA (0.47) | PKMABCB1PIK3CAMEN1KMT2A | |
| SCHEMBL7871226 | 0.89 | ABCB1 (0.48) | PKMABCB1PIK3CAPDE4BPDE4D | |
| SCHEMBL7871187 | 0.88 | PIK3CA (0.47) | PKMABCB1PIK3CAMEN1KMT2A | |
| SCHEMBL7868242 | 0.88 | PIK3CA (0.47) | PKMABCB1PIK3CA | |
| SCHEMBL7864958 | 0.87 | PIK3CA (0.49) | PKMABCB1PIK3CAMEN1KMT2A | |
| SCHEMBL7862243 | 0.87 | PROKR1 (0.44) | PKMABCB1PIK3CAMEN1KMT2A | |
| SCHEMBL7868233 | 0.86 | PIK3CA (0.45) | PKMABCB1PIK3CAMEN1KMT2A | |
| SCHEMBL7870080 | 0.86 | GPR142 (0.47) | PKMABCB1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | PKM 667/4885MAPK1 96/4885ABCB1 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.